- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03939065
Recruitment Status Recruiting
First Posted May 6, 2019
Last update posted August 31, 2020
This research proposes a pilot study using the combination of continuous glucose monitor (CGM) and insulin pump therapy, also known as sensor augmented pump (SAP) therapy, for cystic fibrosis related diabetes (CFRD) management in the inpatient setting, with the aim of improving glycemic control.
|Experimental: Insulin Pump and CGM
Device: Sensor Augmented Pump Therapy
Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
|Other: Standard of Care and CGM
Device: Standard of Care with CGM
Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
1. Age ≥8 years
2. Confirmed diagnosis of CF by consensus guidelines 
3. Diagnosis of CFRD based on American Diabetes Association and CFF criteria 
4. Admission for pulmonary exacerbation
1. Known type 1 or type 2 diabetes, monogenic diabetes (MODY)
2. Critical illness requiring admission to the intensive care unit
3. Admission for indications other than pulmonary exacerbation (ex. Distal intestinal
obstructive syndrome, surgery)
Contact: Rebekah Miller 720-777-2163 email@example.com
Contact: Christine Chan, MD 720-777-0990 firstname.lastname@example.org
United States, Colorado
Children's Hospital Colorado, University of Colorado Denver
University of Colorado, Denver
Cystic Fibrosis Foundation
Principal Investigator: Christine Chan, MD email@example.com